electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award

ECOR 11.20.2024

Full Press ReleaseSEC FilingsOur ECOR Tweets

About Gravity Analytica

Recent News

  • 01.07.2025 - electroCore Expands Intellectual Property Portfolio
  • 12.17.2024 - electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness
  • 11.20.2024 - electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award

Recent Filings

  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.17.2025 - EX-99.1 EX-99.1
  • 01.17.2025 - 8-K Current report

ROCKAWAY, N.J.,Nov. 20, 2024(GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness product, Truvaga Plus, has been recognized in the inaugural Woman’sWorld Magazine50 over 50 Award. Products were evaluated based on quality, effectiveness, and value, with these awards honoring outstanding products for women over 50. A link to the article can be found here: Woman’sWorld 50 Over 50 Awards.

“We are thrilled to receive the Woman’sWorld Magazine50 over 50 Award for Truvaga Plus,” statedDan Goldberger, CEO of electroCore. “This honor highlights our dedication to creating solutions that enhance quality of life by alleviating stress, improving sleep, and sharpening mental focus. We take great pride in Truvaga Plus being recommended by Woman’sWorld Magazine.”

About Woman’sWorld MagazineWoman’s Magazine, published by a360media, is a beloved publication offering diverse content tailored to women’s interests. Known for its engaging and uplifting tone, the magazine covers a wide range of topics, including health, wellness, beauty, fashion, relationships, recipes, and inspirational stories. The magazine reaches a total audience of 5.2 million.

For more information, please visithttps://www.womansworld.com. Such website, and the information on such website, is neither part of this press release nor incorporated by reference herein.

About Truvaga Plus

Truvaga Plus is a revolutionary handheld vagus nerve stimulator that utilizes the company’s proven technology to quickly and gently activate the vagus nerve. It’s designed to work with the body to balance the nervous system to feel calmer, think clearer, and sleep better. Truvaga Plus is intended for general health and wellness purposes only and is not intended to diagnose, cure, mitigate, treat, or prevent any disease.

For more information, please visitwww.truvaga.com.

About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The company’s is focused on the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance inthe United Statesand select overseas markets.

For more information, visitwww.electrocore.com.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects, new and existing wellness product offerings, new ecommerce site, and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments including focus group study results; the Company’s business prospects inthe United States(including its e-commerce initiatives) and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCoreTM, the ability to successfully launch and commercialize Truvaga Plus, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with theSECavailable atwww.sec.gov.

Contact:ECOR Investor Relations(973) 302-9253investors@electrocore.com

Primary Logo

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com